AIV Logo AIV Assistant

Loading...

Logo Stem, Inc. - VSTM Open Stem, Inc. in new tab

7.93 USD
EPS
-3.50
P/B
16.13
ROE
-437.92
Beta
0.89
Target Price
15.50 USD
Stem, Inc. logo

Stem, Inc.

🧾 Earnings Recap – Q3 2025

Verastem Oncology reported strong Q3 results with net product revenue of $11.2 million from the AVMAPKI FAKZYNJA CO-PACK launch, indicating robust adoption by healthcare providers and effective commercial strategies.

  • Net product revenue for Q3 2025 was $11.2 million, exceeding expectations fueled by strong physician engagement and patient initiation.
  • The company successfully achieved its three launch objectives: enhancing physician outreach, supporting patient access, and streamlining reimbursement processes.
  • Over 60% of prescriptions are generated by gynecological oncologists, with a substantial presence in both academic and community practices.
  • Enrollment in clinical trials for AVMAPKI FAKZYNJA CO-PACK and VS-7375 programs remains on track, with positive safety and tolerability data reported.
  • High engagement levels with healthcare providers and effective outreach to patients showcase the brand's strength and market penetration.
📅

7.9300 USD

7.930 USD

Daily: -2.82%
Key Metrics

Earnings date: March 19, 2026

EPS: -3.50

Book Value: 0.59

Price to Book: 16.13

Debt/Equity: 234.95

% Insiders: 0.807%

Growth

Revenue Growth: -0.79%

Estimates

Forward P/E: -3.74

Forward EPS: -2.53

Target Mean Price: 15.50

DCF Valuation

Tweak assumptions to recompute fair value for Stem, Inc. (VSTM)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Logo About Stem, Inc. - (VSTM)

Country: United States

Sector: Information Technology

Website: http://www.stem.com

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Exchange Ticker
LSE (United Kingdom) 0LOV.L
NGM (Sweden) VSTM

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
June 1, 2023 0.080000
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion